Answer
Catridecacog (NovoThirteen) has a geometric mean terminal elimination half-life of 13.7 days (range 10.1–24.6) at steady state in patients with congenital factor XIII A-subunit deficiency receiving 35 IU/kg intravenously every fourth week, based on FXIII activity measured by the Berichrom assay.
Sources for this answer
- NovoThirteen 2500 IU powder and solvent for solution for injectionNovo Nordisk Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 2Document updated
Sources checked